Up next

Autoplay

Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix or Leuprolide

2 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

Show more
0 Comments sort Sort By

Up next

Autoplay